EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Recombinant α1-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a 177Lu-DOTATATE Mouse Radiation Model

Abdul Ghani Alattar iD, Amanda Kristiansson iD, Helena Karlsson, Suvi Vallius, Jonas Ahlstedt, Eva Forssell-Aronsson iD, Bo Åkerström, Sven-Erik Strand iD, Johan Flygare iD, Magnus Gram iD

Biomolecules · 2023

DOI: 10.3390/biom13060928 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Abdul Ghani Alattar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, 221 84 Lund, Sweden. Hauptthemen laut MEDLINE: Octreotide, Organometallic Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crafoordska Foundation, Berta Kamprad Foundation, Alfred Österlunds Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is used clinically to treat metastasized or unresectable neuroendocrine tumors (NETs). Although 177Lu-DOTATATE is mostly well tolerated in patients, bone marrow suppression and long-term renal toxicity are still side effects that should be considered. Amino acids are often used to minimize renal radiotoxicity, however, they are associated with nausea and vomiting in patients. α1-microglobulin (A1M) is an antioxidant with heme- and radical-scavenging abilities. A recombinant form (rA1M) has previously been shown to be renoprotective in preclinical models, including in PRRT-induced kidney damage. Here, we further investigated rA1M’s renal protective effect in a mouse 177Lu-DOTATATE model in terms of administration route and dosing regimen and as a combined therapy with amino acids (Vamin). Moreover, we investigated the protective effect of rA1M on peripheral blood and bone marrow cells, as well as circulatory biomarkers. Intravenous (i.v.) administration of rA1M reduced albuminuria levels and circulatory levels of the oxidative stress-related protein fibroblast growth factor-21 (FGF-21). Dual injections of rA1M (i.e., at 0 and 24 h post-177Lu-DOTATATE administration) preserved bone marrow cellularity and peripheral blood reticulocytes. Administration of Vamin, alone or in combination with rA1M, did not show any protection of bone marrow cellularity or peripheral reticulocytes. In conclusion, this study suggests that rA1M, administered i.v. for two consecutive days in conjunction with 177Lu-DOTATATE, may reduce hematopoietic and kidney toxicity during PRRT with 177Lu-DOTATATE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OctreotideOrganometallic CompoundsMiceAnimalsKidneyDisease Models, AnimalAmino AcidsAlpha-GlobulinsRadionuclide ImagingPositron-Emission Tomography

Stichwörter der Autor:innen

amino acidsbone marrow toxicityoxidative stresspeptide receptor radionuclide therapyradiationrenal damageα1-microglobulin

Substanzen

OctreotideAmino AcidsOrganometallic Compoundsalpha-1-microglobulinAlpha-Globulinscopper dotatate CU-64

Autor:innen und Institutionen

  • Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, 221 84 Lund, Sweden.
  • Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, 221 84 Lund, Sweden.
  • Pediatrics, Department of Clinical Sciences Lund, Skåne University Hospital, Lund University, 221 84 Lund, Sweden.
  • Department of Clinical Sciences Lund, CIPA, Lund University, 221 84 Lund, Sweden.
  • Department of Medical Radiation Sciences, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden.
  • Department of Clinical Sciences Lund, Section for Infection Medicine, Lund University, 221 84 Lund, Sweden.

ORCID-Profile: Abdul Ghani Alattar, Amanda Kristiansson, Eva Forssell-Aronsson, Sven-Erik Strand, Johan Flygare, Magnus Gram

Förderung

  • Crafoordska Foundation
  • Berta Kamprad Foundation
  • Alfred Österlunds Foundation
  • Greta and Johan Kock Foundation
  • Swedish research Council
  • Swedish Cancer Society
  • Guard Therapeutics International

Zitieren

APA

Alattar, A. G., Kristiansson, A., Karlsson, H., Vallius, S., Ahlstedt, J., Forssell-Aronsson, E., Åkerström, B., Strand, S. E., Flygare, J., & Gram, M. (2023). Recombinant α1-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a 177Lu-DOTATATE Mouse Radiation Model. Biomolecules. https://doi.org/10.3390/biom13060928

Vancouver

Alattar AG, Kristiansson A, Karlsson H, Vallius S, Ahlstedt J, Forssell-Aronsson E, et al. Recombinant α1-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a 177Lu-DOTATATE Mouse Radiation Model. Biomolecules. 2023. doi:10.3390/biom13060928

BibTeX
@article{Alattar2023,
  author = {Alattar, Abdul Ghani and Kristiansson, Amanda and Karlsson, Helena and Vallius, Suvi and Ahlstedt, Jonas and Forssell-Aronsson, Eva and Åkerström, Bo and Strand, Sven-Erik and Flygare, Johan and Gram, Magnus},
  title = {Recombinant α1-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a 177Lu-DOTATATE Mouse Radiation Model},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13060928}
}
Kostenlos starten →